These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 22291438
1. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Camm AJ, Toft E, Torp-Pedersen C, Vijayaraman P, Juul-Moller S, Ip J, Beatch GN, Dickinson G, Wyse DG, Scene 2 Investigators. Europace; 2012 Jun; 14(6):804-9. PubMed ID: 22291438 [Abstract] [Full Text] [Related]
9. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Acad Emerg Med; 2010 Nov 25; 17(11):1175-82. PubMed ID: 21175515 [Abstract] [Full Text] [Related]
10. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation. Duggan ST, Scott LJ. Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448 [Abstract] [Full Text] [Related]
11. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Savelieva I, Graydon R, Camm AJ. Europace; 2014 Feb 22; 16(2):162-73. PubMed ID: 24108230 [Abstract] [Full Text] [Related]
16. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Tsuji Y, Dobrev D. Vasc Health Risk Manag; 2013 Feb 22; 9():165-75. PubMed ID: 23637539 [Abstract] [Full Text] [Related]